Trials / Unknown
UnknownNCT04845139
A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Nivolumab given intrathecally is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Detailed description
This is a case study aiming to recruit 1 patient. This study is indicated for relapsed/refractory primary central nervous system lymphoma. Primary objective is to explore the safety.
Conditions
- Refractory Central Nervous System Lymphoma
- Relapsed Primary Central Nervous System Lymphoma
- Primary Central Nervous System Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Nivolumab given intraventricularly |
Timeline
- Start date
- 2022-07-02
- Primary completion
- 2022-10-30
- Completion
- 2022-11-30
- First posted
- 2021-04-14
- Last updated
- 2022-07-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04845139. Inclusion in this directory is not an endorsement.